Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments – Sarepta Therapeutics

ELEVIDYS shipments have resumed for ambulatory individuals living with Duchenne following notification from the U.S. Food and Drug Administration (FDA); continuing to work with FDA on safety labeling process and risk-mitigation approach for non-ambulatory ind…

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com